Dermatology

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

New phase 2b data reveals temtokibart significantly improves atopic dermatitis symptoms in adult patients.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

The label update expands the treatment eligible population to include dystrophic epidermolysis bullosa patients from birth and allows at-home application.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

Red light photodynamic therapy with 10% ALA gel shows superior clearance rates compared to vehicle treatment.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

A new position paper established an evidence-based definition for systemic corticosteroid (SCS) duration in individuals with atopic dermatitis.

These data indicate that greater maternal dietary diversity during pregnancy may be linked with a diminished risk of atopic dermatitis during early childhood.

This study compared a recent risk prediction tool for invasive melanoma and its performance compared to existing prediction tools.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.